trial · primary record
HER3-DXd (FL-DP)
Non-Small Cell Lung Cancer (NSCLC)
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 312 |
| Primary completion | 2027-07-30 |
| Primary endpoint | Dose-limiting toxicities (DLTs) during dose escalation |
| Registry ID | NCT03260491 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:11.559Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03260491
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.